AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 282: L1023-L1030, 2002. First published November 9, 2001; doi:10.1152/ajplung.00409.2000
1040-0605/02 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/5/L1023    most recent
00409.2000v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szilvássy, J.
Right arrow Articles by Szilvássy, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szilvássy, J.
Right arrow Articles by Szilvássy, Z.
Vol. 282, Issue 5, L1023-L1030, May 2002

Feeble bronchomotor responses in diabetic rats in association with decreased sensory neuropeptide release

Judith Szilvássy1, István Sziklai1, Peter Horvath2, Maria Szilasi3, József Németh4, Péter Kovács5, and Zoltán Szilvássy2

Departments of 1 Oto-rhino-laryngology, 3 Pulmonology, 5 Clinical Pharmacology, and 2 Pharmacology, Medical University of Debrecen, H-4032 Debrecen; and 4 Neuroscience Research Group, University Medical School of Pécs, H-7643 Pécs, Hungary

Type I diabetes is associated with a low incidence of asthma. We tested whether a decrease in sensory neuropeptide release is associated with an attenuated bronchoconstrictive response to field stimulation (FS; 100 stimuli, 20 V, 0.1 ms, 20 Hz) in streptozotocin (STZ)-induced diabetes. The organ fluid of the preparations were also tested for substance P, calcitonin gene-related peptide (CGRP), and somatostatin concentrations by RIA. Preparations were from either normal rats or those pretreated with 50 mg/kg STZ iv 8 wk before experiment. A group of STZ-treated animals was supplied with insulin delivery (4 IU/day sc) implants between 4 and 8 wk. A subgroup was formed to study the effect of capsaicin desensitization. The atropine-resistant contraction was attenuated by diabetes without capsaicin-sensitive relaxation response. Exogenous CGRP and substance P potentiated, whereas somatostatin inhibited (1 nM-10 µM) the FS-induced contractions in rings from either group. FS released somatostatin, CGRP, and substance P from 0.17 ± 0.024, 0.15 ± 0.022, and 1.65 ± 0.093 to 0.58 ± 0.032, 0.74 ± 0.122, and 5.34 ± 0.295 in preparations from normal, and from 0.19 ± 0.016, 0.11 ± 0.019, and 0.98 ± 0.116 to 0.22 ± 0.076, 0.34 ± 0.099, and 1.84 ± 0.316 fmol/mg wet wt in preparations from diabetic rats. Insulin supplementation restored neuropeptide release in rings from STZ-treated rats. The results show that the decreased FS-induced contractions occurred with a decrease in sensory neuropeptide release in STZ-diabetic rats.

diabetes; bronchoconstriction; capsaicin





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online